|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Nicardipine#Overdosage]] |
| {{Nicardipine}}
| |
| {{CMG}}; {{AE}}:{{AK}}
| |
| | |
| '''''For patient information about Nicardipine, click [[Nicardipine (patient information)|here]].'''''
| |
| ==OVERDOSAGE==
| |
| Several overdosages with orally administered nicardipine have been reported. One adult patient allegedly ingested 600 mg of immediate-release oral nicardipine, and another patient, 2160 mg of the sustained-release formulation of nicardipine. Symptoms included marked hypotension, [[bradycardia]], palpitations, flushing, drowsiness, confusion and slurred speech. All symptoms resolved without sequelae. An overdosage occurred in a one year old child who ingested half of the powder in a 30 mg nicardipine standard capsule. The child remained asymptomatic.
| |
| Based on results obtained in laboratory animals, lethal overdose may cause systemic hypotension, bradycardia (following initial tachycardia) and progressive atrioventricular conduction block. Reversible hepatic function abnormalities and sporadic focal hepatic necrosis were noted in some animal species receiving very large doses of nicardipine.
| |
| For treatment of overdosage, implement standard measures including monitoring of cardiac and respiratory functions. Position the patient so as to avoid [[cerebral anoxia]]. Use vasopressors for patients exhibiting profound hypotension.<ref> {{cite web | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8ef8420-01d2-11de-a455-0002a5d5c51b | title = CARDENE I.V. (nicardipine hydrochloride) injection, solution [EKR Therapeutics, Inc.] |accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| {{FDA}}
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |